Salarius Pharmaceuticals - SLRX Operatsion marja

Salarius Pharma (SLRX) - korporativ logo

Salarius Pharmaceuticals (SLRX) kompaniyasining istiqbollari kamyob onkologik kasalliklar uchun maqsadli terapiyalarning tijoratlashtirilishiga asoslangan. Operatsion foyda marjasi ushbu tendentsiyani vizuallashtiradi, bunda 0.00 darajasi joriy miqdorni aks ettiradi. Samaradorlik AQSH dagi uchinchi tomon pudratchilari bilan hamkorlik qiluvchi virtual ishlab chiqarish modeli orqali qo'llab-quvvatlanadi. Shu bilan birga, laboratoriya tadqiqotlari davomida asosiy biosafety qoidalariga rioya qilingani sababli ekologik iz minimal darajada qolmoqda.

SLRX - Salarius Pharmaceuticals, Inc. Operatsion marja 04.07.2022 - 08.01.2026 oraligʻida

salariuspharma.com - tahliliy kesimlar va asosiy koʻrsatkichlar (SLRX)

- narx va narxlar bo'yicha konsensus prognoz:
- emitentning bozor qiymati haqida ma'lumotlar:
Kompaniyaning jamlanma tahliliyoti:Salarius, SLRX
Salarius Pharmaceuticals brendining mahsuloti

Operatsion marja moliyaviy xarajatlar va soliqlardan oldingi umumiy tushumda asosiy faoliyatdan olingan foyda ulushini aks ettirib, xarajatlarni boshqarish samaradorligini ko'rsatadi. Operatsion marjaning tarkibiy qismlarini tahlil qilish orqali investor Salarius Pharmaceuticals (SLRX) kompaniyasining kam uchraydigan onkologik kasalliklar uchun maqsadli terapiya ishlanmalarini monetizatsiya qilish qobiliyatini va yuqori R&D xarajatlari sharoitida uning gen modifikatsiyasi platformasining barqarorligini baholaydi.

Salarius Pharmaceuticals raqobatchilari tahlili

Operatsion rentabellik BeiGene Ltd|Halozyme Therapeutics - Operatsion foyda marjasi|Sotuvning operatsion marjasi RVMD (Revolution Medicines Corp)|Operatsion foyda koeffitsiyenti AAPG|Operatsion rentabellik CG Oncology Therapeutics CGON|Operatsion foyda normasi URGN|BCAX: Sotuvning operatsion marjasi|PSNL: Operatsion rentabellik|Erasca (ERAS) - Operatsion rentabellik|DCTH - Operatsion faoliyat rentabelligi|YMAB (Y-mAbs Corp) - Operatsion marja|Sotuvning operatsion marjasi Aura Biosciences (AURA)|Operatsion rentabellik Candel Therapeutics Inc. (CADL)|Sotuvning operatsion marjasi Accuray, Inc. ARAY|Operatsion rentabellik sellaslifesciences.com SLS|Operatsion foyda normasi ACTU|CTOR - Operatsion rentabellik|Operatsion faoliyat rentabelligi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operatsion rentabellik|FATE: Operatsion foyda koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Operatsion marja|TCRX (TScan Therapeutics) - Operatsion foyda koeffitsiyenti|Operatsion rentabellik Champions Oncology (CSBR)|Operatsion faoliyat rentabelligi XBiotech USA|Operatsion rentabellik CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Sotuvning operatsion rentabelligi|RADX - Operatsion rentabellik|ARTV - Operatsion marja|Adlai Nortye Ltd (ANL) - Operatsion rentabellik|Veru Pharma - Operatsion foyda normasi|Operatsion rentabellik Tempest Therapeutics Corp|Operatsion foyda bo'yicha sotuv rentabelligi XLO (Xilio Therapeutics, Inc.)|Operatsion marja RENB|MURA (Mural Oncology) - Operatsion foyda normasi|Operatsion marja KAPA (Kairos Pharma Ltd)|OKUR: Operatsion foyda bo'yicha sotuv rentabelligi|GDTC: Sotuvning operatsion marjasi|CRIS - Operatsion marja|APLM: Operatsion marja|Sotuvning operatsion rentabelligi tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Operatsion marja|Operatsion marja Genprex Inc.|Operatsion marja CLDI|Sotuvning operatsion marjasi Sunshine Biopharma, Inc. SBFM|Operatsion marja XBIO (Xenetic Biosciences)|Operatsion marja purple-biotech.com PPBT|AONC - Operatsion rentabellik|BGNE: Operatsion rentabellik|CKPT: Operatsion marja|Elevation Oncology - Operatsion foyda normasi|ICAD (iCAD) - Operatsion marja|IKNA: Operatsion foyda normasi|Operatsion rentabellik Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operatsion foyda normasi|Operatsion rentabellik MorphoSys Corporation MOR|NAYA: Operatsion foyda bo'yicha sotuv rentabelligi|Ascentage Pharma Group International - Operatsion marja